Regeneron pharmaceuticals incorporated REGN.US 總覽分析
)REGN 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面獲得最高評分，但股利評分未超過2分，若公司開始配息，可能會有更優異的投資結果
REGN 近期報酬表現
-0.30%
Regeneron pharmaceuticals incorporated
0.18%
同產業平均
-2.36%
S&P500
與 REGN 同產業的標的表現
- AMGN Amgen inc價值 4 分趨勢 2 分波段 1 分籌碼 4 分股利 5 分查看更多
REGN 公司資訊
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.